Professor Zanfina Ademi

Professor Zanfina Ademi

Monash University, Melbourne (Australia)

Member of:

Professor Zanfina Ademi leads a program of research around prevention of cardiovascular disease, population genomics, epilepsy management and other health conditions. She also leads a program of research on the Productivity Adjusted Life Years (PALYs), which aim to quantify productivity loss at population level and incorporate productivity explicitly in decision making. She specialises in Health Technology Assessments (HTAs), economic evaluations alongside clinical trials and clinical registries and decision health economic modelling. She has worked in Australia, Finland and Switzerland, leading funded research projects that have provided evidence on cost-effectiveness and return on investment enabling key decision-makers (governments, payers) to enact effective healthcare funding across the world. Currently, she serves in a number of reputable international committees with translational impact, such as the Economics Sub-Committee (ESC) of Australia’s Pharmaceutical Benefit Schemes

Presentations Articles

Early lowering of LDL-C is a more cost-effective strategy than lowering LDL-C later in life: a cost-effectiveness analysis using Mendelian Randomisation

Event: ESC Congress 2023

Topic: Epidemiology

Session: Risk factors and prevention: epidemiology (1)

Access

Dutch Nationwide Implementation Program for familial hypercholesterolemia case finding in children: a cost-effectiveness and return on investment analysis

Event: ESC Congress 2022

Topic: Health Economics

Session: Costs and cost-effectiveness

Access

Population genomic screening of all young adults in Australia to detect familial hypercholesterolemia: a cost-effectiveness analysis

Event: ESC Congress 2021 - The Digital Experience

Topic: Cardiovascular Disease in Primary Care

Session: Highlights from the Young in risk factors revisited

Access

Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: many happy returns on investment?

Event: ESC Congress 2020

Topic: Health Economics

Session: Global and National Trends in Cardiovascular Disease Mortality, Quality of Care and Economics

Access

Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: many happy returns on investment?

Event: ESC Asia with APSC & AFC 2020

Topic: Health Economics

Session: Abstract Programme

Access

Professor Zanfina Ademi

Biography

Contributor content

Early lowering of LDL-C is a more cost-effective strategy than lowering LDL-C later in life: a cost-effectiveness analysis using Mendelian Randomisation

Dutch Nationwide Implementation Program for familial hypercholesterolemia case finding in children: a cost-effectiveness and return on investment analysis

Population genomic screening of all young adults in Australia to detect familial hypercholesterolemia: a cost-effectiveness analysis

Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: many happy returns on investment?

Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: many happy returns on investment?

ESC 365 is supported by